• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在侵袭性念珠菌病和曲霉病的小鼠模型中评估瑞他康唑的治疗效果：关于瑞他康唑疗效的药代动力学/药效学药效学特征的见解。

Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy.

机构信息

Eurofins Panlabs Taipei Taiwan.

Cidara Therapeutics, Inc San Diego CA USA.

出版信息

Pharmacol Res Perspect. 2019 Nov 20;7(6):e00546. doi: 10.1002/prp2.546. eCollection 2019 Dec.

DOI:10.1002/prp2.546
PMID:31763045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6864408/
Abstract

Rezafungin acetate is a novel echinocandin in clinical development for prevention and treatment of invasive fungal infections. Rezafungin is differentiated by a pharmacokinetic/pharmacodynamic (PK/PD) profile that includes a long half-life allowing once-weekly administration, front-loaded plasma drug exposures associated with antifungal efficacy, and penetration into deep-seated infections, such as intra-abdominal abscesses. In this series of in vivo studies, rezafungin demonstrated efficacy in the treatment of neutropenic mouse models of disseminated candidiasis, including infection caused by azole-resistant , and aspergillosis. These results contribute to a growing body of evidence demonstrating the antifungal efficacy and potential utility of rezafungin in the treatment of invasive fungal infections.

摘要

醋酸雷沙康唑是一种新型棘白菌素类药物，目前处于临床开发阶段，用于预防和治疗侵袭性真菌感染。雷沙康唑具有独特的药代动力学/药效学（PK/PD）特征，半衰期长，允许每周给药一次，具有与抗真菌疗效相关的早期高血浆药物暴露，并能渗透到深部感染部位，如腹腔脓肿。在这一系列体内研究中，雷沙康唑在治疗中性粒细胞减少症小鼠播散性念珠菌病模型中显示出疗效，包括由唑类耐药和曲霉引起的感染。这些结果为越来越多的证据提供了支持，证明了雷沙康唑在治疗侵袭性真菌感染方面的抗真菌疗效和潜在用途。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1797/6864408/e855c5514aa3/PRP2-7-e00546-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1797/6864408/9482fadb2587/PRP2-7-e00546-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1797/6864408/38ab04d13691/PRP2-7-e00546-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1797/6864408/e855c5514aa3/PRP2-7-e00546-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1797/6864408/9482fadb2587/PRP2-7-e00546-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1797/6864408/38ab04d13691/PRP2-7-e00546-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1797/6864408/e855c5514aa3/PRP2-7-e00546-g003.jpg

相似文献

1
Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy.在侵袭性念珠菌病和曲霉病的小鼠模型中评估瑞他康唑的治疗效果：关于瑞他康唑疗效的药代动力学/药效学药效学特征的见解。
Pharmacol Res Perspect. 2019 Nov 20;7(6):e00546. doi: 10.1002/prp2.546. eCollection 2019 Dec.
2
Rezafungin: a novel antifungal for the treatment of invasive candidiasis.瑞扎芬净：一种用于治疗侵袭性念珠菌病的新型抗真菌药物。
Future Microbiol. 2021 Jan;16(1):27-36. doi: 10.2217/fmb-2020-0217.
3
Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata.克服耐药障碍：瑞他康唑（CD101）对白色念珠菌和光滑念珠菌的药代动力学-药效学目标达成分析。
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.02614-17. Print 2018 Jun.
4
Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model.测定中性粒细胞减少症小鼠播散性念珠菌病模型中雷泽芬康唑对热带念珠菌和都柏林念珠菌的药效学靶标暴露量。
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01556-19. Print 2019 Nov.
5
Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumonia.雷沙康唑在侵袭性念珠菌病、曲霉病和肺炎预防小鼠模型中的疗效。
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01992-20.
6
Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.一种长效棘白菌素（CD101）及七种对照抗真菌药物在2014年哨兵抗真菌监测项目中针对全球当代侵袭性真菌分离株集合的活性测试。
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02045-16. Print 2017 Mar.
7
Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design.长效棘白菌素 CD101 在延长给药间隔的中性粒细胞减少性侵袭性念珠菌病小鼠模型中的药效学研究。
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.02154-17. Print 2018 Feb.
8
Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus.延长间隔时间给予瑞他康唑治疗唑类耐药烟曲霉。
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.01165-19. Print 2019 Oct.
9
Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).评估 Rezafungin 的 CLSI 临时临床折点和流行病学 cutoff 值，该值针对来自全球范围的同期侵袭性真菌分离株进行了测试（2019 年至 2020 年）。
J Clin Microbiol. 2022 Apr 20;60(4):e0244921. doi: 10.1128/jcm.02449-21. Epub 2022 Mar 7.
10
Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.米卡芬净间歇给药对持续性中性粒细胞减少兔实验性播散性念珠菌病的治疗有效。
Clin Infect Dis. 2015 Dec 1;61 Suppl 6(Suppl 6):S643-51. doi: 10.1093/cid/civ817.

引用本文的文献

1
Aspergillosis: A comprehensive review of pathogenesis, drug resistance, and emerging therapeutics.曲霉病：发病机制、耐药性及新兴治疗方法的全面综述
J Food Drug Anal. 2025 Jun 13;33(2):75-96. doi: 10.38212/2224-6614.3547.
2
Activity of rezafungin against Candida auris.瑞扎芬净对耳念珠菌的活性。
J Antimicrob Chemother. 2025 Apr 30;80(6):1482-93. doi: 10.1093/jac/dkaf124.
3
The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics.瑞扎芬净独特的药代动力学特征，这是一种在现代药物计量学时代研发的长效棘白菌素。

本文引用的文献

1
Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus.延长间隔时间给予瑞他康唑治疗唑类耐药烟曲霉。
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.01165-19. Print 2019 Oct.
2
Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model.抗真菌药物 Rezafungin（CD101）对中性粒细胞减少症小鼠侵袭性念珠菌病模型中念珠菌属的药效学评价。
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01572-18. Print 2018 Nov.
3
Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species.
J Antimicrob Chemother. 2025 Jan 3;80(1):18-28. doi: 10.1093/jac/dkae415.
4
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.新型抗真菌药物和治疗方法，以应对耐药性并改善侵袭性真菌感染的治疗结局。
Clin Microbiol Rev. 2024 Jun 13;37(2):e0007423. doi: 10.1128/cmr.00074-23. Epub 2024 Apr 11.
5
An Insight into the Repurposing of Phytoconstituents obtained from Delhi's Aravalli Biodiversity Park as Antifungal Agents.探讨德里阿拉瓦利生物多样性公园获得的植物成分的再利用作为抗真菌剂。
Infect Disord Drug Targets. 2024;24(7):e020224226666. doi: 10.2174/0118715265282411240119061441.
6
Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antifungal Agents: A Review.EMA 批准的抗真菌药物研发过程中的临床前药代动力学/药效学研究和临床试验：综述。
Clin Pharmacokinet. 2024 Jan;63(1):13-26. doi: 10.1007/s40262-023-01327-2. Epub 2023 Nov 16.
7
The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective.新型抗真菌药物在念珠菌病治疗中的作用：临床视角。
Mycopathologia. 2023 Dec;188(6):937-948. doi: 10.1007/s11046-023-00759-5. Epub 2023 Jul 20.
8
Rezafungin: First Approval.雷沙康唑：首次批准。
Drugs. 2023 Jun;83(9):833-840. doi: 10.1007/s40265-023-01891-8.
9
Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations.无临床意义的药物相互作用 Rezafungin：研究结果。
Microbiol Spectr. 2023 Jun 15;11(3):e0133923. doi: 10.1128/spectrum.01339-23. Epub 2023 May 8.
10
Biocontrol of by Antagonistic Microorganisms and Bioactive Compounds.利用拮抗微生物和生物活性化合物对……进行生物防治 。（原文“Biocontrol of by...”中“of”后面缺少具体对象）
Antibiotics (Basel). 2022 Sep 12;11(9):1238. doi: 10.3390/antibiotics11091238.
雷泽凡辛（CD101）对曲霉菌具有强大的体外活性，包括唑类耐药的烟曲霉菌分离株和隐球菌种。
J Antimicrob Chemother. 2018 Nov 1;73(11):3063-3067. doi: 10.1093/jac/dky280.
4
Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model.评估新型棘白菌素类药物瑞他康唑在免疫抑制小鼠模型中治疗播散性耳念珠菌感染的疗效。
J Antimicrob Chemother. 2018 Aug 1;73(8):2085-2088. doi: 10.1093/jac/dky153.
5
Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata.克服耐药障碍：瑞他康唑（CD101）对白色念珠菌和光滑念珠菌的药代动力学-药效学目标达成分析。
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.02614-17. Print 2018 Jun.
6
Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris.长效棘白菌素CD101对耳念珠菌临床分离株的活性。
Diagn Microbiol Infect Dis. 2018 Mar;90(3):196-197. doi: 10.1016/j.diagmicrobio.2017.10.021. Epub 2017 Nov 7.
7
We can do better: a fresh look at echinocandin dosing.我们可以做得更好：棘白菌素类药物剂量的新视角。
J Antimicrob Chemother. 2018 Jan 1;73(suppl_1):i44-i50. doi: 10.1093/jac/dkx448.
8
Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design.长效棘白菌素 CD101 在延长给药间隔的中性粒细胞减少性侵袭性念珠菌病小鼠模型中的药效学研究。
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.02154-17. Print 2018 Feb.
9
Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters.CD101 疗效的药理学基础：暴露形状很重要。
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.00758-17. Print 2017 Nov.
10
Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model.阐明棘白菌素类抗真菌药在腹腔脓肿模型感染部位的药物渗透情况。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.01009-17. Print 2017 Oct.